English
French
Press Release
|
02 |
Oct 2024 |
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG... |
|
19 |
Jul 2024 |
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process... |
|
03 |
Jul 2024 |
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Pa... |
|
11 |
Jun 2024 |
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process... |
|
28 |
May 2024 |
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process... |
|
17 |
May 2024 |
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives... |
|
08 |
May 2024 |
IntelGenx Announces Voting Results on Election of Directors... |
|
08 |
Apr 2024 |
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Cl... |
|
05 |
Apr 2024 |
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA... |
|
21 |
Mar 2024 |
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results... |
|
14 |
Mar 2024 |
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow... |
|
11 |
Mar 2024 |
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences... |
|
20 |
Feb 2024 |
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering... |
|
20 |
Feb 2024 |
IntelGenx Launches Preferred Share Regulation A Offering... |
|
05 |
Feb 2024 |
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform... |